Donna, We give a lot of FEC (5FU + epirubicin + cytoxan) and taxanes for our breast cancer patients. We have always used almost exclusively ports, but are now using more and more PICCs. Nearly no Hickmans. We also wish to get a more individualized VAD choice process, with consideration taken to patient preferences.
Mats Den 05-12-23 00.04, skrev "Fritz, Donna" <[EMAIL PROTECTED]>: > I'm addressing bullet point #3. I think you will have to look at what chemo > is giving in your area for breast ca treatment. We're doing adriamycin + > cytoxan, followed by a taxane, usually taxol. It's usually given on an every > 3 week basis for several months. It seems an ideal circumstance for a port. > > I think your line has to match the type of therapy patients will receive. For > colon patients receiving continuous 5FU, an externalized tunneled cath seems > more suited. > > Unfortunately, our physicians make the choice without presenting options to > the patient, but this is kind of how they decide. No evidence basis here. > > Donna Fritz, RN, MN, OCN > Oncology CNS > > > > -----Original Message----- > From: [EMAIL PROTECTED] > [mailto:[EMAIL PROTECTED] Behalf Of Mats Strömberg > Sent: Thursday, December 22, 2005 11:32 AM > To: Venous > Subject: Spam: Breast cancer VAD choice > > > Dear listers, > > I am going to write about half a page on vascular access device choice for > breast cancer patients. It is part of a larger set of guidelines for breast > cancer. > > The things I would like to address are: > - The importance of early assessment > - The advantages of central venous access devices (like better hemodilution > preserving the veins, lower risk for extravasation) > - The individual advantages of implanted ports, PICCs and Hickman lines > - When to opt for peripheral access > > Is this the things that I should address? > > I need to show the evidence base for everything. What is the evidence for > these things? What is the important litterature to use as references? > > Thanks in advance > Mats in Stockholm > > ---- > Mats Strömberg, RN, Research nurse > Dept. of Oncology > Karolinska University Hospital, Solna > SE-171 76 Stockholm > > E-mail: [EMAIL PROTECTED] > Phone int: +46 8 517 76376 > Mobile phone int: +46 70 471 6661 > > > > > > ***************************************************************************** > This communication is for the use of the intended recipient only. It may > contain information that is privileged and confidential. If you are not the > intended recipient of this communication, any disclosure, copying, further > distribution or use thereof is prohibited. If you have received this > communication in error, please advise me by return e-mail or by telephone and > delete/destroy > it. ************************************************************************** > ***
